NINGBO INNO PHARMCHEM CO.,LTD. is proud to highlight Ceritinib, a cutting-edge Active Pharmaceutical Ingredient (API) that marks a significant stride in targeted cancer therapy. As a leading manufacturer and supplier of high-quality pharmaceutical raw materials, we are committed to providing APIs that meet stringent global standards, empowering advancements in healthcare worldwide.

Ceritinib, chemically identified as 5-Chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine, is a small molecule drug characterized by its white to pale yellow crystalline powder appearance. With a molecular formula of C28H36ClN5O3S and a molecular weight of 558.14 g/mol, it demonstrates exceptional purity, typically exceeding 99% as verified by HPLC analysis. While exhibiting limited solubility in aqueous solutions, Ceritinib shows good solubility in organic solvents like dimethyl sulfoxide (DMSO). Its structural integrity is confirmed through advanced analytical techniques, including FTIR, UV-Vis spectroscopy, and NMR, ensuring its quality and consistency for pharmaceutical applications.

The primary therapeutic application of Ceritinib lies in its role as a potent and selective inhibitor of anaplastic lymphoma kinase (ALK). This makes it indispensable in the treatment of ALK-positive metastatic non-small cell lung cancer (NSCLC). Ceritinib functions by competitively binding to the ATP-binding site of ALK, thereby effectively blocking crucial downstream signaling pathways that drive cancer cell proliferation and survival. Notably, its efficacy extends beyond wild-type ALK, demonstrating superior potency against various crizotinib-resistant mutants, such as L1196M and G1269A, addressing a critical need for patients who have progressed on or are intolerant to prior ALK inhibitor therapies. Clinical studies have also underscored its ability to penetrate the blood-brain barrier, offering significant benefits for patients with central nervous system metastases, a common challenge in advanced NSCLC.

Beyond NSCLC, Ceritinib shows promising potential in other ALK-rearranged malignancies, including inflammatory myofibroblastic tumors and anaplastic large cell lymphoma, underscoring its broad therapeutic applicability. The drug's pharmacokinetic profile is characterized by rapid absorption and a terminal half-life of approximately 41 hours, facilitating effective systemic exposure. As with any potent therapeutic agent, careful monitoring is essential; common adverse effects include gastrointestinal disturbances, hepatotoxicity, and hyperglycemia. NINGBO INNO PHARMCHEM CO.,LTD. emphasizes adherence to all regulatory guidelines and recommendations for handling and use of this API to ensure patient safety and optimal therapeutic outcomes.

The development of Ceritinib represents a significant advancement in the field of precision oncology, offering a lifeline for patients with specific genetic mutations. NINGBO INNO PHARMCHEM CO.,LTD. is dedicated to supporting pharmaceutical development globally by supplying premium-grade Ceritinib. For detailed specifications, pricing, or to purchase this vital pharmaceutical intermediate, please contact our sales team. We are your reliable Ceritinib manufacturer and Ceritinib supplier, ready to facilitate your research and production needs. Discover the competitive Ceritinib price and explore options to buy Ceritinib from a trusted source, ensuring the highest standards for your formulations.